Anakinra: an effective treatment in the Schnitzler syndrome

Joint Bone Spine. 2011 Dec;78(6):636-7. doi: 10.1016/j.jbspin.2011.03.021. Epub 2011 May 6.

Abstract

Schnitzler syndrome is a rare disease characterized by chronic urticarial eruption and a monoclonal gammapathy. The exact pathogenesis is still unclear and treatment remains a challenge. We report the case of a patient with a 2-year history of arthralgia, chronic urticaria rash and fever, not responding to different treatments including anti-histaminics, corticosteroids, colchicine and low dose methotrexate. A diagnostic of Schnitzler syndrome was suggested and treatment with anakinra, an interleukin-1 receptor antagonist, was started, leading to a rapid, complete and sustained remission of symptoms. Anakinra seems to constitute an efficient and safe therapeutic approach for this rare disease.

Publication types

  • Case Reports

MeSH terms

  • Antirheumatic Agents / therapeutic use*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / therapeutic use*
  • Male
  • Middle Aged
  • Receptors, Interleukin-1 / antagonists & inhibitors
  • Remission Induction
  • Schnitzler Syndrome / drug therapy*
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1